Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19
George R. Painter, Michael G. Natchus, Oren J. Cohen, et al.
Current Opinion in Virology (2021) Vol. 50, pp. 17-22
Open Access | Times Cited: 157

Showing 26-50 of 157 citing articles:

The Natural Stilbenoid (–)-Hopeaphenol Inhibits Cellular Entry of SARS-CoV-2 USA-WA1/2020, B.1.1.7, and B.1.351 Variants
Ian Tietjen, Joel Cassel, Emery T. Register, et al.
Antimicrobial Agents and Chemotherapy (2021) Vol. 65, Iss. 12
Open Access | Times Cited: 41
Fabrication of novel quantum dots for the estimation of COVID-19 antiviral drug using green chemistry: application to real human plasma
Baher I. Salman, Adel Ehab Ibrahim, Sami El Deeb, et al.
RSC Advances (2022) Vol. 12, Iss. 26, pp. 16624-16631
Open Access | Times Cited: 35
New Perspectives on Antimicrobial Agents: Molnupiravir and Nirmatrelvir/Ritonavir for Treatment of COVID-19
Robert L. Atmar, Natalie Finch
Antimicrobial Agents and Chemotherapy (2022) Vol. 66, Iss. 8
Open Access | Times Cited: 35
Real-world experience with molnupiravir during the period of SARS-CoV-2 Omicron variant dominance
Robert Flisiak, Dorota Zarębska‐Michaluk, Magdalena Rogalska, et al.
Pharmacological Reports (2022) Vol. 74, Iss. 6, pp. 1279-1285
Open Access | Times Cited: 32
Innovative eco-friendly stability-indicating HPLC-PDA method for simultaneous determination of the emerging antiviral drugs against COVID-19 infection molnupiravir and favipiravir; degradation kinetic studies along with LC-MS based structure elucidation
Hoda M. Marzouk, Amira S. Gouda, Mamdouh R. Rezk, et al.
Microchemical Journal (2024) Vol. 205, pp. 111197-111197
Closed Access | Times Cited: 7
Surface engineering of carbon microspheres with nanoceria wrapped on MWCNTs: a dual electrocatalyst for simultaneous monitoring of molnupiravir and paracetamol
Yahya S. Alqahtani, Ashraf M. Mahmoud, Mohamed M. El‐Wekil, et al.
RSC Advances (2024) Vol. 14, Iss. 8, pp. 5406-5416
Open Access | Times Cited: 5
Hydrogen bonding in the crystal structure of molnupiravir Form I, C13H19N3O7
Tawnee M. Ens, James A. Kaduk, M. Rost, et al.
Powder Diffraction (2025), pp. 1-4
Closed Access
Computational drug repurposing: approaches, evaluation of in silico resources and case studies
Ziaurrehman Tanoli, Adrià Fernández‐Torras, Umut Onur Özcan, et al.
Nature Reviews Drug Discovery (2025)
Closed Access
Molnupiravir: From Hope to Epic Fail?
Daniele Focosi
Viruses (2022) Vol. 14, Iss. 11, pp. 2560-2560
Open Access | Times Cited: 26
Drug Repositioning with GraphSAGE and Clustering Constraints Based on Drug and Disease Networks
Yuchen Zhang, Xiujuan Lei, Yi Pan, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 22
Development and validation of molnupiravir assessment in bulk powder and pharmaceutical formulation by the RP-HPLC-UV method
Abdelaziz M. Annadi, Noha M. El Zahar, Nour E. A. Abd El‐Sattar, et al.
RSC Advances (2022) Vol. 12, Iss. 53, pp. 34512-34519
Open Access | Times Cited: 22
A broad-spectrum macrocyclic peptide inhibitor of the SARS-CoV-2 spike protein
Vito Thijssen, Daniel L. Hurdiss, Oliver J. Debski-Antoniak, et al.
Proceedings of the National Academy of Sciences (2023) Vol. 120, Iss. 26
Open Access | Times Cited: 15
Synthetic Approaches to the New Drugs Approved During 2021
Emma L. McInturff, Scott P. France, Carolyn A. Leverett, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 15, pp. 10150-10201
Closed Access | Times Cited: 15
Preparation and Characterization of Fe-Gallic acid MOF for determination of antiviral Molnupiravir as inhibitor for RNA Corona virus replication
Huda M. Younis, Ahmed O. Youssef, Said M. El‐Sheikh, et al.
Microchemical Journal (2023) Vol. 194, pp. 109297-109297
Closed Access | Times Cited: 14
Evaluating Multienzyme Cascade Routes for Pharmaceutically Relevant Molecules
Karishma Naik, Sangoji Dheeraj, Kodru Jeevani, et al.
European Journal of Organic Chemistry (2024) Vol. 27, Iss. 8
Closed Access | Times Cited: 4
The impact of remdesivir on SARS-CoV-2 evolution in vivo
Ted Ling-Hu, Lacy M. Simons, Estefany Rios-Guzman, et al.
JCI Insight (2025)
Open Access
A Tale of Two Drugs: Molnupiravir and Paxlovid
Michael D. Waters, Stafford G. Warren
Mutation Research/Reviews in Mutation Research (2025) Vol. 795, pp. 108533-108533
Closed Access
Structural Virology: The Key Determinants in Development of Antiviral Therapeutics
Tanuj Handa, Ankita Saha, Aarthi Narayanan, et al.
Viruses (2025) Vol. 17, Iss. 3, pp. 417-417
Open Access
An Overview of Marketed Nucleoside and Nucleotide Analogs
Steven De Jonghe, Piet Herdewijn
Current Protocols (2022) Vol. 2, Iss. 3
Open Access | Times Cited: 21
Industrially Relevant Enzyme Cascades for Drug Synthesis and Their Ecological Assessment
Regine Siedentop, Katrin Rosenthal
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 7, pp. 3605-3605
Open Access | Times Cited: 20
Repurposing of antiviral drugs for COVID-19 and impact of repurposed drugs on the nervous system
Madhura Punekar, Manas M. Kshirsagar, Chaitanya Tellapragada, et al.
Microbial Pathogenesis (2022) Vol. 168, pp. 105608-105608
Open Access | Times Cited: 20
Drug-Repurposing Screening Identifies a Gallic Acid Binding Site on SARS-CoV-2 Non-structural Protein 7
Yushu Gu, Miaomiao Liu, Bart L. Staker, et al.
ACS Pharmacology & Translational Science (2023) Vol. 6, Iss. 4, pp. 578-586
Open Access | Times Cited: 10
Viral target and metabolism‐based rationale for combined use of recently authorized small molecule COVID‐19 medicines: Molnupiravir, nirmatrelvir, and remdesivir
Daisy Yan, Bingfang Yan
Fundamental and Clinical Pharmacology (2023) Vol. 37, Iss. 4, pp. 726-738
Open Access | Times Cited: 10
A path from synthesis to emergency use authorization of molnupiravir as a COVID-19 therapy
Norein Sakander, Ajaz Ahmed, Mahir Bhardwaj, et al.
Bioorganic Chemistry (2024) Vol. 147, pp. 107379-107379
Closed Access | Times Cited: 3
Early Kilogram Scale Delivery of MK-7845 as a Potential COVID-19 Therapy: Rapid Process Development of Key Intermediates
Feng Peng, Ji Qi, Jin Zhang, et al.
Organic Process Research & Development (2024) Vol. 28, Iss. 6, pp. 2150-2156
Closed Access | Times Cited: 3

Scroll to top